We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Xentria announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its intravenous TNF-α inhibitor, XTMAB-16, for the treatment of sarcoidosis.
In very preliminary findings, an existing rheumatoid arthritis drug appeared to cure one woman of a rare but potentially life-threatening condition known as sarcoidosis.....